Article Figures & Data
Figures
- Fig 1.
Reader preference for gadobenate dimeglumine or gadodiamide based on blinded qualitative evaluation. Each reader expresses a highly significant (P < .0001) preference for gadobenate dimeglumine for each parameter. Note that the number of patients for whom equality is expressed is not shown.
- Fig 2.
Glioblastoma with recurrent disease. This 55-year-old woman shows more conspicuous enhancement (arrows) in the right posterior temporal lobe with gadobenate dimeglumine than gadodiamide for both SE and GRE sequences. Although there are differences in angulation, changes were confirmed by review of all adjacent sections.
- Fig 3.
A 32-year-old woman with primary cerebellar glioma, which had previously been resected. A solid nodule of enhancement (arrow) is seen convincingly on the gadobenate dimeglumine–enhanced image. The clear visualization of contrast enhancement was important in postoperative decision making.
- Fig 4.
A 46-year-old man with a primary anaplastic carcinoma of the small bowel who developed sensory changes in the left upper extremity. The solitary metastasis (arrow) in the right superior frontal gyrus is only visualized on the gadobenate dimeglumine–enhanced image.
Tables
- Table 1:
Qualitative assessments of patients with glial tumors, metastases, and extra-axial lesions
Diagnostic Information End Point Reader Glial Tumors (n = 47) Metastases (n = 27) Extra-Axial Lesions (n = 18) Gadobenate Dimeglumine Preferred (%) Gadodiamide Preferred (%) P Gadobenate Dimeglumine Preferred (%) Gadodiamide Preferred (%) P Gadobenate Dimeglumine Preferred (%) Gadodiamide Preferred P Global diagnostic preference 1 22 (46.8%) 1 (2.1) <.0001 20 (74.1) 2 (7.4) <.0001 14 (77.8) 0 .0001 2 35 (74.5) 1 (2.1) <.0001 18 (66.7) 1 (3.7) <.0001 13 (72.2) 0 .0002 3 25 (53.2) 1 (2.1) <.0001 19 (70.4) 2 (7.4) <.0001 16 (88.9) 0 <.0001 Lesion border delineation 1 15 (31.9) 1 (2.1) .0005 18 (66.7) 1 (3.7) <.0001 1 (5.6) 0 1.00 2 18 (38.3) 1 (2.1) <.0001 17 (63.0) 0 <.0001 3 (16.7) 0 .25 3 16 (34.0) 1 (2.1) .0003 17 (63.0) 2 (7.4) .0007 7 (38.9) 0 .0156 Definition of disease extent 1 8 (17.0) 0 .0078 13 (48.1) 1 (3.7) .0018 1 (5.6) 0 1.00 2 7 (14.9) 0 .0156 13 (48.1) 1 (3.7) .0018 2 (11.1) 0 .50 3 7 (14.9) 0 .0156 16 (59.3) 1 (3.7) .0003 1 (5.6) 0 1.00 Visualization of lesion internal morphology 1 10 (21.3) 0 .002 13 (48.1) 1 (3.7) .0018 2 (11.1) 0 .50 2 14 (29.8) 0 .0001 13 (48.1) 0 .0002 3 (16.7) 0 .25 3 8 (17.0) 0 .0078 14 (51.9) 2 (7.4) .0042 4 (22.2%) 0 .125 Lesion contrast enhancement 1 23 (48.9) 1 (2.1) <.0001 20 (74.1) 2 (7.4) <.0001 15 (83.3) 0 .0001 2 35 (74.5) 2 (4.3) <.0001 17 (63.0) 1 (3.7) 0.0001 14 (77.8) 0 .0001 3 2 (55.3) 1 (2.1) <.0001 20 (74.1) 2 (7.4) <.0001 16 (88.9) 0 <.0001 - Table 2:
Reasons for global diagnostic preference as expressed by expert blinded neuroradiologists
Specifications of Global Diagnostic Preference Reader 1 (n = 66) Preference Expressed Reader 2 (n = 79) Reader 3 (n= 76) Gadobenate Dimeglumine (n= 63) (%) Gadodiamide (n= 3) (%) Gadobenate Dimeglumine (n = 77) (%) Gadodiamide (n = 2) (%) Gadobenate Dimeglumine (n= 73) (%) Gadodiamide (n = 3) (%) Superior contrast enhancement 63 (95.5) 2 (3.0) 74 (93.7) 2 (2.5) 73 (96.1) 3 (3.9) Better delineation of normal structures 0 0 7 (8.9) 0 3 (3.9) 0 Better delineation of at least 1 lesion 33 (50.0) 1 (1.5) 39 (49.4) 0 44 (57.9) 3 (3.9) Better visualization of lesion internal structure 10 (15.2) 0 30 (38.0) 0 19 (25.0) 0 Detection of more lesions 3 (4.8) 1 (1.5) 3 (3.8) 1 (1.3) 2 (2.6) 1 (1.3) Greater diagnostic confidence 10 (15.2) 0 10 (12.7) 1 (1.3) 10 (13.2%) 0 - Table 3:
Comparison of CNR values on T1SE and T1GRE sequences after administration of gadobenate dimeglumine and gadodiamide for all evaluated lesions and for lesion subsets
Lesion Type Reader Postdose SE Sequences Postdose GRE Sequences Mean CNR Values % Increase in CNR with Gadobenate Dimeglumine (P) Mean CNR Values % Increase in CNR with Gadobenate Dimeglumine (P) Gadobenate Dimeglumine Gadodiamide Gadobenate Dimeglumine Gadodiamide All lesions 1 61.07 46.65 30.9 <.0001 32.26 22.65 42.4 <.0001 2 46.46 37.67 23.3 <.0001 23.59 16.19 45.7 <.0001 3 54.71 40.62 34.7 <.0001 26.56 17.84 48.9 <.0001 Glial tumors 1 47.08 35.28 33.5 .0002 30.57 21.67 41.1 .0068 2 39.95 32.97 21.2 .0125 22.80 15.81 44.2 .0002 3 43.84 36.82 19.1 .0993 25.08 20.01 25.3 .0466 Metastases 1 60.97 46.52 31.1 .0162 27.41 20.63 32.9 .0261 2 46.23 37.32 23.9 .0119 24.14 16.02 50.7 <.0001 3 51.27 37.63 36.2 .0098 24.81 15.46 60.5 .0004 Extra-axial lesions 1 80.57 67.17 19.9 .0046 41.44 28.83 43.7 .0021 2 62.61 49.21 27.2 .0388 27.30 20.19 35.2 .0031 3 77.12 54.18 42.3 <.0001 33.97 21.10 61.0 <.0001 Note:—SE indicates spin-echo; GRE, gradient recalled-echo; CNR, contrast-to-noise ratio.
In this issue
Jump to section
Related Articles
Cited By...
- Reply:
- The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)
- Gadolinium Contrast Agents for CNS Imaging: Current Concepts and Clinical Evidence
- Multicenter, Intraindividual Comparison of Single-Dose Gadobenate Dimeglumine and Double-Dose Gadopentetate Dimeglumine for MR Angiography of the Supra-Aortic Arteries (the Supra-Aortic VALUE Study)
- Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT Study)
- MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice
- Correlations between Perfusion MR Imaging Cerebral Blood Volume, Microvessel Quantification, and Clinical Outcome Using Stereotactic Analysis in Recurrent High-Grade Glioma
- Comparative Studies of Different Gadolinium Agents in Brain Tumors: Differences between Gadolinium Chelates and Their Possible Influence on Imaging Features
- Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine
- MR Imaging in Multiple Sclerosis: Review and Recommendations for Current Practice
- Comparison of Gadobenate Dimeglumine and Gadodiamide in the Evaluation of Spinal Vascular Anatomy with MR Angiography